Type 3 IP3 receptors driving oncogenesis |
| |
| Institution: | 1. Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX;2. Department of Internal Medicine, Oncology Division, University of Texas Medical School at Houston, Houston, TX;3. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX;4. Department of Diagnostic Radiology and Nuclear Medicine, Houston Methodist Hospital, Houston, TX;5. Department of Radiation Oncology, Houston Methodist Hospital, Cancer Center and Research Institute, Houston, TX;1. Department of Anaesthesiology and Intensive Care, National Institute of Oncology;2. Department of Thoracic Surgery, National Institute of Oncology;3. Thoracic Surgery Department on the base of National Institute of Oncology, Semmelweis University;4. Medical University of Vienna;1. Department of Biophysics and Physiology, Federal University of Minas Gerais (UFMG), MG, Brazil;2. Department of Molecular Medicine, Federal University of Minas Gerais (UFMG), MG, Brazil;3. Section of Digestive Disease, Department of Internal Medicine, Yale University School of Medicine, CT, United States;4. Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials, SP, Brazil;5. Department of Pathologic Anatomy, Medicine School of Federal University of Minas Gerais (UFMG), MG, Brazil;6. Department of Surgery, Medicine School of Federal University of Minas Gerais (UFMG), MG, United States;1. School of Biological Sciences and Institute for Global Food Security, Queen''s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast, BT9 7BL, UK;2. School of Pharmacy and Biomolecular Sciences, University of Brighton, Huxley Building, Lewes Road, Brighton, BN2 4GJ, UK;3. From the Department of Pharmacology and Toxicology, State University of New York at Buffalo, Buffalo, New York 14214,;4. Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263;5. Department of Psychiatry, Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York 10016 |
| |
| Abstract: | Type 3 Inositol 1,4,5-trisphosphate (IP3) receptors (IP3R3s) have been identified as anti-oncogenic channels by propelling pro-apoptotic Ca2+ signals to mitochondria. Yet, recent studies (Rezuchova et al, Cell Death Dis, 2019; Ueasilamongkol et al, Hepathology, 2019; Guerra et al, Gut, 2019) revealed that IP3R3 upregulation drives oncogenesis via ER-mitochondrial Ca2+ crosstalk, adding complexity to IP3R3’s role in cancer. |
| |
| Keywords: | ITPR3 IP3R3 channels Calcium signaling Cancer Oncogenesis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
